KATHRYN STOVALL: Open Payments
NPI 1225266497 · GREENSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$722 in 45 payments from 14 companies in 2025. Trend: 2023 $545 · 2024 $555 · 2025 $722
Food & beverage: $722
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 19 | $176 |
| Calliditas Therapeutics US Inc. | 3 | $96 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Travere Therapeutics, Inc. | 3 | $63 |
| Fresenius USA Marketing, Inc. | 3 | $54 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Ardelyx, Inc. | 2 | $37 |
| Vifor Pharma, Inc. | 2 | $35 |
| Novo Nordisk Inc | 2 | $35 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
Products named: Fabhalta, TARPEYO, JYNARQUE, VELPHORO, BENLYSTA, IBSRELA, Veltassa, FARXIGA.
Industry payments across NC — which companies pay providers there.
